Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Clinical Trial to Confirm the Safety of TREAKISYM Liquid Formulation (Rapid Infusion Injection Formulation)

Next Previous
Search
Trial Profile

Phase III Clinical Trial to Confirm the Safety of TREAKISYM Liquid Formulation (Rapid Infusion Injection Formulation)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bendamustine (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Registrational
  • Sponsors SymBio Pharmaceuticals

    • Most Recent Events

    • 10 May 2021 According to a Eagle Pharmaceuticals media release, the company has filed TREAKISYM RI (50ml) liquid formulation with the Pharmaceuticals and Medical Devices Agency ("PMDA") in Japan, based on data from this study.
    • 09 Sep 2020 According to a SymBio Pharmaceuticals media release, the company submitted a New Drug Application for marketing authorization of TREAKISYM ready to dilute liquid formulation in September 2019.
    • 09 Sep 2020 According to a SymBio Pharmaceuticals media release, the company has completed the observation period for all patients (last patient last visit)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top